Edgewise Therapeutics, Inc.EWTXNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-110.34M
↓ 104% below average
Average (5y)
$-54.10M
Historical baseline
Range
High:$-9.35M
Low:$-110.34M
CAGR
+63.8%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-110.34M | -12.9% |
| 2023 | $-97.69M | -67.9% |
| 2022 | $-58.18M | -70.2% |
| 2021 | $-34.17M | -130.3% |
| 2020 | $-14.84M | -58.7% |
| 2019 | $-9.35M | - |